1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,225 | 4,635 | 16:07 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15:29 | Xspray Pharma Signs License Agreement With Handa Therapeutics For Dasatinib Product | 1 | RTTNews | ||
| 13:18 | Xspray Pharma Signs License Agreement with Handa Therapeutics - to Receive up to Double-Digit Royalty on Handa's Net Proceeds | 159 | Business Wire | Xspray Pharma ("Xspray") has entered into a license agreement with Handa Therapeutics ("Handa") granting Handa a non-exclusive license to certain Xspray patents. The license covers commercialization... ► Artikel lesen | |
| 08:20 | XSpray Pharma AB: Xspray Pharma signs license agreement with Handa Therapeutics - to receive up to double-digit royalty on Handa's net proceeds | 67 | GlobeNewswire (Europe) | Xspray Pharma ("Xspray") has entered into a license agreement with Handa Therapeutics ("Handa") granting Handa a non-exclusive license to certain Xspray patents. The license covers commercialization... ► Artikel lesen | |
| 11.07. | XSpray Pharma AB: XSpray Pharma achieves significant milestone - demonstrating bioequivalence with absorption advantages compared to Tasigna | 112 | GlobeNewswire (Europe) | Xspray Pharma has now completed the population pharmacokinetic (PopPK) modeling that constitutes key regulatory documentation ahead of submitting a New Drug Application (NDA) for the product candidate... ► Artikel lesen | |
| XSPRAY PHARMA Aktie jetzt für 0€ handeln | |||||
| 27.06. | XSpray Pharma AB: Xspray Pharma Passes FDA Pre-Approval Inspection - Key Regulatory Milestone Achieved for Dasynoc | 364 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) today announces that the U.S. Food and Drug Administration (FDA) has conducted a successful Pre-Approval Inspection (PAI) of the company's manufacturing lines, located at a contract... ► Artikel lesen | |
| 14.05. | XSpray Pharma AB: FDA sets PDUFA-date for Xspray Pharma's re-submitted application for Dasynoc | 180 | GlobeNewswire (Europe) | The U.S. Food and Drug Administration (FDA) has acknowledged receipt of Xspray Pharma's re-submitted NDA (New Drug Application) for Dasynoc®. The re-submission is based on a CRL (Complete Response Letter)... ► Artikel lesen | |
| 13.05. | XSpray Pharma AB: Bulletin from the annual general meeting of Xspray Pharma AB (publ) | 96 | GlobeNewswire (Europe) | The following resolutions were passed at the annual general meeting (the "AGM") of Xspray Pharma AB (publ) ("Xspray") on 13 May 2025.
Adoption of income statement and balance sheet for the financial... ► Artikel lesen | |
| 07.05. | XSpray Pharma AB: Interim Report First Quarter 2025 | 111 | GlobeNewswire (Europe) | January - March 2025, Group• Net sales amounted to SEK 0 thousand (0)• Earnings before tax amounted to SEK -42,321 thousand (-67,781)• Earnings per share before dilution amounted to SEK -1.14 (-2.17)•... ► Artikel lesen | |
| 08.04. | XSpray Pharma AB: Xspray Pharma re-submits its FDA application | 216 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) has re-submitted its application for market approval for Dasynoc®, the company's lead product candidate, an amorphous dasatinib for the treatment of leukemia. The application... ► Artikel lesen | |
| 12.02. | XSpray Pharma AB: Interim Report Fourth Quarter 2024 | 100 | GlobeNewswire (Europe) | October-December 2024, GroupNet sales amounted to SEK 0 thousand (0)Loss before tax amounted to SEK -82,002 thousand (-54,513)Earnings per share before dilution amounted to SEK -2.36 (-1.85)Cash flow... ► Artikel lesen | |
| 20.01. | XSpray Pharma AB: Xspray Pharma reports strong interim data for product candidate XS003 - confirms plan to apply for market approval in H1 2025 | 129 | GlobeNewswire (Europe) | Xspray Pharma AB (publ) today presents interim data from a food interaction study with the nilotinib product candidate (XS003). The results confirm the benefits of the company's patented HyNap technology... ► Artikel lesen | |
| 14.11.24 | Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of Xspray Pharma AB | 363 | GlobeNewswire | With effect from November 15, 2024, the subscription rights of Xspray Pharma
AB will be traded on the list for Equity rights. Trading will continue up until
and including November 26, 2024.
Instrument:... ► Artikel lesen | |
| 12.11.24 | XFRA CAPITAL ADJUSTMENT INFORMATION - 12.11.2024 | 2.597 | Xetra Newsboard | Das Instrument 3O41 BMG611881019 LIBERTY GLOBAL LTD CL.A EQUITY wird cum Kapitalmassnahme gehandelt am 12.11.2024 und ex Kapitalmassnahme am 13.11.2024 The instrument 3O41 BMG611881019 LIBERTY GLOBAL... ► Artikel lesen | |
| 06.11.24 | XSpray Pharma AB: Interim Report Third Quarter 2024 | 169 | GlobeNewswire (Europe) | July - September 2024, GroupNet sales amounted to SEK 0 thousand (0)Loss before tax amounted to SEK -82,272 thousand (-38,942)Earnings per share before dilution amounted to SEK -2.44 (-1.59)Cash flow... ► Artikel lesen | |
| 06.11.24 | XSpray Pharma AB: Xspray resolves on a rights issue of approximately SEK 135 million and raises a loan of SEK 100 million | 221 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH... ► Artikel lesen | |
| 19.09.24 | Xspray Pharma AB: Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission | 351 | Business Wire | Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a pharmaceutical company leveraging its proprietary HyNap technology to develop enhanced cancer therapies, today announced significant progress... ► Artikel lesen | |
| 06.09.24 | Scientific Article in Leading Journal Endorses Xspray Pharma's HyNap Technology | 467 | Business Wire | A new scientific article, published in the US journal Clinical Pharmacology in Drug Development, shows how Xspray Pharma's HyNap technology improves the bioavailability and reduces variability of... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,355 | +0,58 % | Qiagen übertrifft Erwartungen in 2Q - Prognose für Gesamtjahr angehoben | DJ Qiagen übertrifft Erwartungen in 2Q - Prognose für Gesamtjahr angehoben
DOW JONES--Qiagen hat mit den Ergebnissen für das zweite Quartal die Erwartungen übertroffen und den Ausblick für das... ► Artikel lesen | |
| EVOTEC | 6,530 | -0,67 % | Evotec Aktie: Die Bullen in der Falle? | Die Evotec Aktie steht erneut im Zentrum charttechnischer Spannung. Nachdem der Kurs der Biotech-Aktie Ende Juli kurzzeitig über die 200-Tage-Linie ausgebrochen war, entpuppte sich dieser Anstieg schnell... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 50,08 | 0,00 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
| NUVALENT | 74,95 | 0,00 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| VALNEVA | 3,998 | +9,24 % | Valneva: FDA gibt Chikungunya-Impfstoff IXCHIQ wieder frei | Valneva hat bekanntgegeben, dass die US-Arzneimittelbehörde FDA die zuvor empfohlene Einschränkung für den Chikungunya-Impfstoff IXCHIQ bei Personen ab 60 Jahren aufgehoben hat. Zugleich wurde eine... ► Artikel lesen | |
| BIONTECH | 94,90 | +0,80 % | BioNTech Aktie: Krebsforschung rückt stärker in den Vordergrund | Analysten haben ihre Einschätzungen für die BioNTech Aktie nach den Zahlen zum zweiten Quartal bestätigt. Die Kursziele in drei aktuellen Analystenstudien bewegen sich für die Biotech-Aktie zwischen... ► Artikel lesen | |
| ARCELLX | 69,14 | 0,00 % | Arcellx GAAP EPS of -$0.94 beats by $0.10, revenue of $7.55M misses by $6.37M | ||
| 180 LIFE SCIENCES | 5,110 | +52,08 % | 180 Life Sciences stock soars after revealing massive ETH holdings | ||
| HARMONY BIOSCIENCES | 34,830 | 0,00 % | Mizuho raises Harmony Biosciences stock price target to $50 on increased confidence | ||
| PRAXIS PRECISION MEDICINES | 44,950 | 0,00 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 32,730 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $625 - $640 million -- KPL-387... ► Artikel lesen | |
| BB BIOTECH | 32,950 | -0,60 % | Aktien KW 30 - Weg erst durch EU-US-Zolleinigung frei? Warten bis zum 1. August? Oder TACO? Bis dahin Einzelwerte im Fokus. News. Evotec. Almonty. Heidelberger Druck. ThyssenKrupp nucera. HELLA. Palfinger. BB Biotech. Sartorius. Berentzen. GFT. STEYR Moto | Aktien: Diese Woche Einzelwerte mit Zahlen im Fokus - Berichtssaison lässt grüssen. Puma bricht ein, Evotec nach unten durchgereicht. Aber auch das: Deutsche Bank zweistelliger Kurssprung. Und so setzte... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 53,28 | 0,00 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update | Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 17,260 | +5,37 % | ARS Pharmaceuticals, Inc.: EURneffy (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) | EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions ALK-Abelló A/S, which owns the rights to... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 13,190 | 0,00 % | Earnings Preview For Mineralys Therapeutics |
XSPRAY PHARMA AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 4,210 Euro und damit -0,47 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XSPRAY PHARMA AB finden Sie auf Wallstreet Online.